Targeting airway inflammation

Novel therapies for the treatment of asthma

Research output: Contribution to journalLiterature review

31 Citations (Scopus)

Abstract

It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. Inhaled corticosteroids remain the most important anti-inflammatory treatment for asthma. However, they are rather non-specific in their actions and their use raises concerns over side effects and compliance issues, particularly in children and adolescents. Moreover, a significant sub-group of asthmatic patients responds poorly or not at all to high-dose inhaled or systemic steroid treatment. Therefore, much effort is being made to develop novel more specific and safer therapy for asthma. Significant areas of drug development include humanised monoclonal antibodies (mAb) for asthma therapy including those against IL-4, IL-5, TNF and IL-13. Asthma-relevant cytokines or chemokines have been targeted in a number of other ways. These include: (1) the use of humanised blocking mAb to their receptors; (2) removal of cytokines or chemokines via binding to soluble receptors or small molecule receptor antagonists; and (3) drugs that block the signal transduction pathways activated following the interaction of cytokines or chemokines with their receptors. Another approach is to use anti-inflammatory cytokines directly or encourage their production thereby suppressing the allergic inflammatory process; these chemokines include IL-10, IL-12 and IFN-gamma. Finally, a further promising area involves targeting the allergic portion of the asthma phenotype using humanised anti-IgE mAb. This review will discuss the current status, therapeutic potential and potential problems of these novel drug developments in asthma therapy.

Original languageEnglish
Pages (from-to)3105-3111
Number of pages7
JournalCurrent Medicinal Chemistry
Volume13
Issue number25
DOIs
Publication statusPublished - 2006

Keywords

  • severe persistent asthma
  • chemokine receptor CCR3
  • necrosis-factor-alpha
  • anti-ige antibody
  • T-cell peptides
  • allergic asthma
  • monoclonal antibody
  • controlled trial
  • interleukin-5 receptor
  • pulmonary eosinophilia

Cite this

Targeting airway inflammation : Novel therapies for the treatment of asthma. / Walsh, Garry Michael.

In: Current Medicinal Chemistry, Vol. 13, No. 25, 2006, p. 3105-3111.

Research output: Contribution to journalLiterature review

@article{910c7aee2c744e53b7c7328dbec71174,
title = "Targeting airway inflammation: Novel therapies for the treatment of asthma",
abstract = "It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. Inhaled corticosteroids remain the most important anti-inflammatory treatment for asthma. However, they are rather non-specific in their actions and their use raises concerns over side effects and compliance issues, particularly in children and adolescents. Moreover, a significant sub-group of asthmatic patients responds poorly or not at all to high-dose inhaled or systemic steroid treatment. Therefore, much effort is being made to develop novel more specific and safer therapy for asthma. Significant areas of drug development include humanised monoclonal antibodies (mAb) for asthma therapy including those against IL-4, IL-5, TNF and IL-13. Asthma-relevant cytokines or chemokines have been targeted in a number of other ways. These include: (1) the use of humanised blocking mAb to their receptors; (2) removal of cytokines or chemokines via binding to soluble receptors or small molecule receptor antagonists; and (3) drugs that block the signal transduction pathways activated following the interaction of cytokines or chemokines with their receptors. Another approach is to use anti-inflammatory cytokines directly or encourage their production thereby suppressing the allergic inflammatory process; these chemokines include IL-10, IL-12 and IFN-gamma. Finally, a further promising area involves targeting the allergic portion of the asthma phenotype using humanised anti-IgE mAb. This review will discuss the current status, therapeutic potential and potential problems of these novel drug developments in asthma therapy.",
keywords = "severe persistent asthma, chemokine receptor CCR3, necrosis-factor-alpha, anti-ige antibody, T-cell peptides, allergic asthma, monoclonal antibody, controlled trial, interleukin-5 receptor, pulmonary eosinophilia",
author = "Walsh, {Garry Michael}",
year = "2006",
doi = "10.2174/092986706778521779",
language = "English",
volume = "13",
pages = "3105--3111",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "25",

}

TY - JOUR

T1 - Targeting airway inflammation

T2 - Novel therapies for the treatment of asthma

AU - Walsh, Garry Michael

PY - 2006

Y1 - 2006

N2 - It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. Inhaled corticosteroids remain the most important anti-inflammatory treatment for asthma. However, they are rather non-specific in their actions and their use raises concerns over side effects and compliance issues, particularly in children and adolescents. Moreover, a significant sub-group of asthmatic patients responds poorly or not at all to high-dose inhaled or systemic steroid treatment. Therefore, much effort is being made to develop novel more specific and safer therapy for asthma. Significant areas of drug development include humanised monoclonal antibodies (mAb) for asthma therapy including those against IL-4, IL-5, TNF and IL-13. Asthma-relevant cytokines or chemokines have been targeted in a number of other ways. These include: (1) the use of humanised blocking mAb to their receptors; (2) removal of cytokines or chemokines via binding to soluble receptors or small molecule receptor antagonists; and (3) drugs that block the signal transduction pathways activated following the interaction of cytokines or chemokines with their receptors. Another approach is to use anti-inflammatory cytokines directly or encourage their production thereby suppressing the allergic inflammatory process; these chemokines include IL-10, IL-12 and IFN-gamma. Finally, a further promising area involves targeting the allergic portion of the asthma phenotype using humanised anti-IgE mAb. This review will discuss the current status, therapeutic potential and potential problems of these novel drug developments in asthma therapy.

AB - It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. Inhaled corticosteroids remain the most important anti-inflammatory treatment for asthma. However, they are rather non-specific in their actions and their use raises concerns over side effects and compliance issues, particularly in children and adolescents. Moreover, a significant sub-group of asthmatic patients responds poorly or not at all to high-dose inhaled or systemic steroid treatment. Therefore, much effort is being made to develop novel more specific and safer therapy for asthma. Significant areas of drug development include humanised monoclonal antibodies (mAb) for asthma therapy including those against IL-4, IL-5, TNF and IL-13. Asthma-relevant cytokines or chemokines have been targeted in a number of other ways. These include: (1) the use of humanised blocking mAb to their receptors; (2) removal of cytokines or chemokines via binding to soluble receptors or small molecule receptor antagonists; and (3) drugs that block the signal transduction pathways activated following the interaction of cytokines or chemokines with their receptors. Another approach is to use anti-inflammatory cytokines directly or encourage their production thereby suppressing the allergic inflammatory process; these chemokines include IL-10, IL-12 and IFN-gamma. Finally, a further promising area involves targeting the allergic portion of the asthma phenotype using humanised anti-IgE mAb. This review will discuss the current status, therapeutic potential and potential problems of these novel drug developments in asthma therapy.

KW - severe persistent asthma

KW - chemokine receptor CCR3

KW - necrosis-factor-alpha

KW - anti-ige antibody

KW - T-cell peptides

KW - allergic asthma

KW - monoclonal antibody

KW - controlled trial

KW - interleukin-5 receptor

KW - pulmonary eosinophilia

U2 - 10.2174/092986706778521779

DO - 10.2174/092986706778521779

M3 - Literature review

VL - 13

SP - 3105

EP - 3111

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 25

ER -